Clinically, growth retardation is not uncommon in children with rheumatic diseases, for example, about 41% of patients with systemic juvenile rheumatoid arthritis (Still’s disease) can develop growth retardation, which can lead to short stature and seriously affect the quality of life in the future if left untreated. The causes of growth retardation are mainly related to the use of hormones and the inflammation of the disease itself. Hormones are commonly used in the treatment of rheumatic diseases in children, which can promote protein degradation, inhibit protein synthesis and affect the release of growth hormone, etc. Long-term use may increase the risk of growth retardation in children. Therefore, during treatment, the dose of hormones should be reduced as much as possible, and other immunosuppressive drugs should be added to promote the reduction of hormones, and alternate day hormones can also be used to reduce the risk of growth retardation. In addition, several studies have shown that long-term treatment with growth hormone is effective in children with rheumatic diseases who have growth retardation, and that children with mild to moderate disease activity and low doses of hormone have a significantly better effect on growth hormone than those with significant disease activity. For patients with growth hormone receptor deficiency, treatment with insulin-like growth factor-1 is also an option. Inflammation of the disease itself also contributes to growth retardation in children with rheumatic diseases. If inflammatory cytokines including TNF-α, IL-1β and IL-6 are increased in the child, they can inhibit the growth hormone/insulin-like growth factor-1 axis or inhibit bone growth surface chondrocytes, thus affecting the child’s growth. Anti-TNF-α antagonists such as Classic, Ixipro, Enzyme and Xumel help to restore the growth rate of children while relieving inflammation, and also facilitate the growth of children because they are hormone co-reducers.